Golf club captain raises £2,550 for choroideremia research

12 May 2010

Shooters Hill cheque presentation

Tony Christini, the captain of Shooters Hill Golf Club in Blackheath, and his partner Carol have raised over £2,550 for the Tommy Salisbury Choroideremia Committee. The funds raised will support research into choroideremia - a rare genetic eye condition that affects ten-year-old Tommy Salisbury.

Tommy was presented with a cheque for £2,550 at the golf club where his grandparents, Dot and Alan Grindley, are members. Tommy’s parents, Emma and Paul Salisbury, are extremely grateful for the ongoing support of the club: "We would like to thank Tony and Carol for their fantastic fundraising efforts and all members of Shooters Hill Golf Club who supported them."

The Tommy Salisbury Choroideremia Committee is supporting research into choroideremia at Imperial College London. The total raised by the committee since 2005 now stands at £160,000.

[ends]

For more information contact
Louise Elliott at Fight for Sight on 020 7929 7755
or email press@fightforsight.org.uk

Note for Editors:
Fight for Sight is the UK’s leading charity dedicated to funding world-class research into the prevention and treatment of blindness and eye disease.

Since 1965, the charity has funded millions of pounds worth of research at leading universities and hospitals throughout the UK. Our major achievements in this time include:
• saving the sight of thousands of premature babies through understanding and controlling levels of oxygen delivery;
• restoring sight by establishing the UK Corneal Transplant Service enabling over 45,000 corneal transplants to take place;
• revolutionising the treatment for children with amblyopia (lazy eye);
• bringing hope to children with inherited eye disease by helping fund the team responsible for the world’s first gene therapy clinical trial; and
• providing £1million for the research unit at the dedicated children’s eye centre at Moorfields Eye Hospital.

Fight for Sight’s current research programme of over £5 million focuses on preventing and treating age-related macular degeneration, diabetic retinopathy, glaucoma, cataract and the causes of childhood blindness.

Go back